Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
Barzin Y. Nabet(Gene Therapy Laboratory), David S. Shames(Gene Therapy Laboratory), Joseph M. Chan(Memorial Sloan Kettering Cancer Center), Leah Adler(Roche (Switzerland)), Matthew Fernandez, Myung Chang Lee, Hartmut Koeppen, Stephen V. Liu(Georgetown University), Lisa McGinnis(Stanford Medicine), John V. Heymach(The University of Texas MD Anderson Cancer Center), John D. Minna(Center for Neuro-Oncology), Charles M. Rudin(Memorial Sloan Kettering Cancer Center), Romain Banchereau(Kaiser Permanente San Francisco Medical Center), Carl M. Gay(The University of Texas MD Anderson Cancer Center), Martin Reck(German Center for Lung Research), Velimir Gayevskiy(Rancho BioSciences (United States)), Habib Hamidi(Unknown), Lauren A. Byers(The University of Texas MD Anderson Cancer Center), Minu K. Srivastava, Sandra Rost, Namrata S. Patil(Gene Therapy Laboratory), Caleb Chan, Patrick Chang, Kiandra A. Smith, Ahmed M. Elhossiny, Stefanie Morris(Roche (Switzerland)), Rajiv Jesudason
Cited by 154
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
|Journal of Clinical Oncology|2009|1.5k